Advertisement

The European Journal of Health Economics

, Volume 19, Issue 3, pp 341–353 | Cite as

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation

  • Dirk Müller
  • Marion Danner
  • Kerstin Rhiem
  • Björn Stollenwerk
  • Christoph Engel
  • Linda Rasche
  • Lisa Borsi
  • Rita Schmutzler
  • Stephanie Stock
Original Paper

Abstract

Background

Women with a BRCA1 or BRCA2 mutation are at increased risk of developing breast and/or ovarian cancer. This economic modeling study evaluated different preventive interventions for 30-year-old women with a confirmed BRCA (1 or 2) mutation.

Methods

A Markov model was developed to estimate the costs and benefits [i.e., quality-adjusted life years (QALYs), and life years gained (LYG)] associated with prophylactic bilateral mastectomy (BM), prophylactic bilateral salpingo-oophorectomy (BSO), BM plus BSO, BM plus BSO at age 40, and intensified surveillance. Relevant input data was obtained from a large German database including 5902 women with BRCA 1 or 2, and from the literature. The analysis was performed from the German Statutory Health Insurance (SHI) perspective. In order to assess the robustness of the results, deterministic and probabilistic sensitivity analyses were performed.

Results

With costs of €29,434 and a gain in QALYs of 17.7 (LYG 19.9), BM plus BSO at age 30 was less expensive and more effective than the other strategies, followed by BM plus BSO at age 40. Women who were offered the surveillance strategy had the highest costs at the lowest gain in QALYs/LYS. In the probabilistic sensitivity analysis, the probability of cost-saving was 57% for BM plus BSO. At a WTP of 10,000 € per QALY, the probability of the intervention being cost-effective was 80%.

Conclusions

From the SHI perspective, undergoing BM plus immediate BSO should be recommended to BRCA 1 or 2 mutation carriers due to its favorable comparative cost-effectiveness.

Keywords

Cost-effectiveness Economic modeling Breast cancer Risk-reducing surgery BRCA 

Supplementary material

10198_2017_887_MOESM1_ESM.docx (223 kb)
Supplementary material 1 (DOCX 223 kb)

References

  1. 1.
    Global Burden of Disease Cancer Collaboration: The global burden of cancer 2013. JAMA Oncol 1(4), 505–527 (2015)CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Robert-Koch Institut, Zentrum für Krebsregisterdaten: Brustkrebs (Mammakarzinom). http://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html (2015). Accessed 28 Apr2016
  3. 3.
    Rhiem, K., Engel, C., Graeser, M., et al.: The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 14(6), R156 (2012). doi: 10.1186/bcr3369 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Luengo-Fernandez, R., Leal, J., Gray, A., et al.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14(12), 1165–1174 (2013). doi: 10.1016/S1470-2045(13)70442-X CrossRefPubMedGoogle Scholar
  5. 5.
    Willems, R.A., Bolman, C.A., Mesters, I., et al.: Cancer survivors in the first year after treatment: the prevalence and correlates of unmet needs in different domains. Psycho-oncology (2015). doi: 10.1002/pon.3870 PubMedGoogle Scholar
  6. 6.
    Sorensen, S.V., Goh, J.W., Pan, F., et al.: Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int. J. Technol. Assess. Health Care 28(1), 12–21 (2012). doi: 10.1017/S026646231100064X CrossRefPubMedGoogle Scholar
  7. 7.
    Foster, T.S., Miller, J.D., Boye, M.E., et al.: The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat. Rev. 37(6), 405–415 (2011). doi: 10.1016/j.ctrv.2010.12.008 PubMedGoogle Scholar
  8. 8.
    Cohn, D.E., Kim, K.H., Resnick, K.E., et al.: At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 29(10), 1247–1251 (2011). doi: 10.1200/JCO.2010.32.1075 CrossRefPubMedGoogle Scholar
  9. 9.
    Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer. National Institute for Health and Clinical Excellence: Guidance. Cardiff (UK) (2013)Google Scholar
  10. 10.
    Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Langversion 3.0, Aktualisierung 2012, AWMF-Register-Nummer: 032–045OLGoogle Scholar
  11. 11.
    Nelson, H.D., Pappas, M., Zakher, B., et al.: Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann. Intern. Med. 160(4), 255–266 (2014). doi: 10.7326/M13-1684 CrossRefPubMedGoogle Scholar
  12. 12.
    Phillips, K.A., Milne, R.L., Rookus, M.A., et al.: Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 31(25), 3091–3099 (2013). doi: 10.1200/JCO.2012.47.8313 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Grann, V.R., Patel, P.R., Jacobson, J.S., et al.: Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res. Treat. 125(3), 837–847 (2011). doi: 10.1007/s10549-010-1043-4 CrossRefPubMedGoogle Scholar
  14. 14.
    Anderson, K., Jacobson, J.S., Heitjan, D.F., et al.: Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann. Intern. Med. 144(6), 397–406 (2006)CrossRefPubMedGoogle Scholar
  15. 15.
    Norum, J., Hagen, A.I., Maehle, L., et al.: Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur. J. Cancer 44(7), 963–971 (2008). doi: 10.1016/j.ejca.2008.02.025 CrossRefPubMedGoogle Scholar
  16. 16.
    Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: Allgmeine Methoden. Version 4.2 vom 22.04.2015. https://www.iqwig.de/download/IQWiG_Methoden_Version_4-2.pdf (2015). Accessed 28 Apr 2016
  17. 17.
    Schad, M., John, J.: Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis. Eur. J. Health Econ 13(2), 127–144 (2012). doi: 10.1007/s10198-010-0292-9 CrossRefPubMedGoogle Scholar
  18. 18.
    Chen, T., Jansen, L., Gondos, A., et al.: Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage. Eur. J. Cancer Prev. 22(1), 59–67 (2013). doi: 10.1097/CEJ.0b013e3283552e28 CrossRefPubMedGoogle Scholar
  19. 19.
    Holleczek, B., Brenner, H.: Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany. BMC Cancer 12, 317 (2012). doi: 10.1186/1471-2407-12-317 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    German Consortium for Hereditary Breast and Ovarian Cancer. http://www.krebshilfe.de/wir-helfen/adressen/familiaerer-krebs/brustkrebszentren.html (2016). Accessed 28 Apr 2016
  21. 21.
    The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Chapter 13: Including non-randomized studies. http://handbook.cochrane.org/chapter_13/13_including_non_randomized_studies.htm (2011). Accessed 31 Jan 2017
  22. 22.
    Land, L.H., Dalton, S.O.: Jensen, et al.: impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008. Breast Cancer Res. Treat. 131(3), 1013–1020 (2012). doi: 10.1007/s10549-011-1819-1 CrossRefPubMedGoogle Scholar
  23. 23.
    Rebbeck, T.R., Lynch, H.T., Neuhausen, S.L., et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346(21), 1616–1622 (2002). doi: 10.1056/NEJMoa012158 CrossRefPubMedGoogle Scholar
  24. 24.
    Domchek, S.M., Friebel, T.M., Singer, C.F., et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9), 967–975 (2010). doi: 10.1001/jama.2010.1237 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mavaddat, N., Peock, S., Frost, D., et al.: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl. Cancer Inst. 105(11), 812–822 (2013). doi: 10.1093/jnci/djt095 CrossRefPubMedGoogle Scholar
  26. 26.
    Boughey, J.C., Hoskin, T.L., Degnim, A.C., et al.: Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann. Surg. Oncol. 17(10), 2702–2709 (2010). doi: 10.1245/s10434-010-1136-7 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Grann, V.R., Jacobson, J.S., Sundararajan, V., et al.: The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J Sci Am 5(5), 283–292 (1999)PubMedGoogle Scholar
  28. 28.
    Grann, V.R., Patel, P., Bharthuar, A., et al.: Breast cancer-related preferences among women with and without BRCA mutations. Breast Cancer Res. Treat. 119(1), 177–184 (2010). doi: 10.1007/s10549-009-0373-6 CrossRefPubMedGoogle Scholar
  29. 29.
    Peasgood, T., Ward, S.E., Brazier, J.: Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res 10(5), 553–566 (2010). doi: 10.1586/erp.10.65 CrossRefPubMedGoogle Scholar
  30. 30.
    Havrilesky, L.J., Broadwater, G., Davis, D.M., et al.: Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol. Oncol. 113(2), 216–220 (2009). doi: 10.1016/j.ygyno.2008.12.026 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ara, R., Wailoo, A.: Using health state utility values in models exploring the cost-effectiveness of health technologies. Value Health 15(6), 971–974 (2012). doi: 10.1016/j.jval.2012.05.003 CrossRefPubMedGoogle Scholar
  32. 32.
    Federal Statistical Office of Germany: Life expectancy 2015. https://www.destatis.de/EN/FactsFigures/SocietyState/Population/Deaths/Deaths.html (2015). Accessed 28 Apr 2016
  33. 33.
    Metcalfe, K., Lynch, H.T., Ghadirian, P., et al.: Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 127(1), 287–296 (2011). doi: 10.1007/s10549-010-1336-7 CrossRefPubMedGoogle Scholar
  34. 34.
    Litiere, S., Werutsky, G., Fentiman, I.S., et al.: Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 13(4), 412–419 (2012). doi: 10.1016/S1470-2045(12)70042-6 CrossRefPubMedGoogle Scholar
  35. 35.
    Winter, W.E., Maxwell, G.L., Tian, C., Gynecologic Oncology Group Study, et al.: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25(24), 3621–3627 (2007)CrossRefPubMedGoogle Scholar
  36. 36.
    Rebbeck, T.R., Friebel, T., Lynch, H.T., et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 22(6), 1055–1062 (2004). doi: 10.1200/JCO.2004.04.188 CrossRefPubMedGoogle Scholar
  37. 37.
    Sullivan, P.W., Lawrence, W.F., Ghushchyan, V.: A national catalog of preference-based scores for chronic conditions in the United States. Med. Care 43(7), 736–749 (2005)CrossRefPubMedGoogle Scholar
  38. 38.
    Dawood, S.: Triple-negative breast cancer: epidemiology and management options. Drugs 70(17), 2247–2258 (2010). doi: 10.2165/11538150-000000000-00000 CrossRefPubMedGoogle Scholar
  39. 39.
    Holleczek, B., Jansen, L., Brenner, H.: Breast cancer survival in Germany: a population-based high resolution study from Saarland. PLoS One 8(7), e70680 (2013). doi: 10.1371/journal.pone.0070680 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Hess, K.R., Esteva, F.J.: Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res. Treat. 137(2), 449–455 (2013). doi: 10.1007/s10549-012-2366-0 CrossRefPubMedGoogle Scholar
  41. 41.
    Inwald, E.C., Ortmann, O., Zeman, F., et al.: Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry. Biomed. Res. Int. 2014, 137304 (2014). doi: 10.1155/2014/137304 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    DeKoven, M., Bonthapally, V., Jiao, X., et al.: Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey. J Comp Eff Res 1(5), 453–463 (2012). doi: 10.2217/cer.12.43 CrossRefPubMedGoogle Scholar
  43. 43.
    Dufresne, A., Pivot, X., Tournigand, C., et al.: Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res. Treat. 107(2), 275–279 (2008). doi: 10.1007/s10549-007-9550-7 CrossRefPubMedGoogle Scholar
  44. 44.
    Martin, L.P., Schilder, R.J.: Management of recurrent ovarian carcinoma: current status and future directions. Semin. Oncol. 36(2), 112–125 (2009). doi: 10.1053/j.seminoncol.2008.12.003 CrossRefPubMedGoogle Scholar
  45. 45.
    Modesitt, S.C., Jazaeri, A.A.: Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin. Pharmacother. 8(14), 2293–2305 (2007). doi: 10.1517/14656566.8.14.2293 CrossRefPubMedGoogle Scholar
  46. 46.
    Lux, M.P., Reichelt, C., Wallwiener, D., et al.: Results of the Zometa cost-utility model for the German healthcare system based on the results of the ABCSG-12 study. Onkologie 33(7), 360–368 (2010). doi: 10.1159/000315699 CrossRefPubMedGoogle Scholar
  47. 47.
    Universitätsklinikum Münster DRG Research Group Medizinisches Management: Webgrouper. http://drg.uni-muenster.de/index.php?option=com_webgrouper&view=webgrouper&Itemid=26 (2015). Accessed 28 Apr 2016
  48. 48.
    Rote Liste® Service GmbH: Rote Liste. http://www.rote-liste.de/ (2015). Accessed 28 Apr 2016
  49. 49.
    Kassenärztliche Bundesvereinigung: Uniform value scale. http://www.kbv.de/html/ebm.php (2015). Accessed 28 Apr 2016
  50. 50.
    Arican, A., Bozkurt, T., Bozcuk, H., et al.: A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support. Care Cancer 22(10), 2629–2634 (2014). doi: 10.1007/s00520-014-2253-9 CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Verband der Ersatzkassen: Rahmenverträge und Vergütungslisten bei Heilmitteln.. http://www.vdek.com/vertragspartner/heilmittel/rahmenvertrag.html (2015). Accessed 28 Apr 2016
  52. 52.
    IntelliMed GmbH.:Catalog of therapeutic products. http://www.heilmittelkatalog.de/heilmittelkatalog-online.html (2014). Accessed 28 Apr 2016
  53. 53.
  54. 54.
    Fryback, D.G., Chinnis Jr., J.O., Ulvila, J.W.: Bayesian cost-effectiveness analysis. An example using the GUSTO trial. Int. J. Technol. Assess. Health Care 17(1), 83–97 (2001)CrossRefPubMedGoogle Scholar
  55. 55.
    Stinnett, A.A., Mullahy, J.: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Decis. Making 18(2 Suppl), S68–S80 (1998)CrossRefPubMedGoogle Scholar
  56. 56.
    Geiger, A.M., Nekhlyudov, L., Herrinton, L.J., et al.: Quality of life after bilateral prophylactic mastectomy. Ann. Surg. Oncol. 14(2), 686–694 (2007). doi: 10.1245/s10434-006-9206-6 CrossRefPubMedGoogle Scholar
  57. 57.
    Rebbeck, T.R., Mitra, N., Wan, F., et al.: Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13), 1347–1361 (2015). doi: 10.1001/jama.2014.5985 CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Chai, X., Friebel, T.M., Singer, C.F., et al.: Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 148(2), 397–406 (2014). doi: 10.1007/s10549-014-3134-0 CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Cappelli, M., Surh, L., Humphreys, L., et al.: Measuring women’s preferences for breast cancer treatments and BRCA1/BRCA2 testing. Qual. Life Res. 10(7), 595–607 (2001)CrossRefPubMedGoogle Scholar
  60. 60.
    Hildebrandt, T., Thiel, F.C., Fasching, P.A., et al.: Health utilities in gynecological oncology and mastology in Germany. Anticancer Res. 34(2), 829–835 (2014)PubMedGoogle Scholar
  61. 61.
    Parkin, D., Devlin, N.: Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ. 15(7), 653–664 (2006). doi: 10.1002/hec.1086 CrossRefPubMedGoogle Scholar
  62. 62.
    Greiner, W., Claes, C., Busschbach, J.J., von der Schulenburg, J.M.: Validating the EQ-5D with time trade off for the German population. Eur. J. Health Econ. 6(2), 124–130 (2005)CrossRefPubMedGoogle Scholar
  63. 63.
    Chan, Y.M., Ngan, H.Y., Li, B.Y., et al.: A longitudinal study on quality of life after gynecologic cancer treatment. Gynecol. Oncol. 83(1), 10–19 (2001). doi: 10.1006/gyno.2001.6345 CrossRefPubMedGoogle Scholar
  64. 64.
    den Heijer, M., Seynaeve, C., Timman, R., et al.: Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study. Eur. J. Cancer 48(9), 1263–1268 (2012). doi: 10.1016/j.ejca.2011.10.020 CrossRefGoogle Scholar
  65. 65.
    den Heijer, M., Seynaeve, C., Vanheusden, K., et al.: Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. Psycho-Oncology 22(3), 598–604 (2013). doi: 10.1002/pon.3039 CrossRefGoogle Scholar
  66. 66.
    Hooker, G.W., King, L., Vanhusen, L., et al.: Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers. Hered Cancer Clin Pract 12(1), 9 (2014). doi: 10.1186/1897-4287-12-9 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Dirk Müller
    • 1
  • Marion Danner
    • 1
  • Kerstin Rhiem
    • 2
  • Björn Stollenwerk
    • 3
  • Christoph Engel
    • 4
  • Linda Rasche
    • 5
  • Lisa Borsi
    • 1
  • Rita Schmutzler
    • 2
  • Stephanie Stock
    • 1
  1. 1.Institute for Health Economics and Clinical EpidemiologyThe University Hospital of Cologne (AöR)CologneGermany
  2. 2.Center for Hereditary Breast and Ovarian CancerThe University Hospital of Cologne (AöR)CologneGermany
  3. 3.Institute of Health Economics and Health Care ManagementHelmholtz Zentrum München-German Research Center for Environmental HealthNeuherbergGermany
  4. 4.Institute for Medical Informatics, Statistics and Epidemiology (IMISE)University of LeipzigLeipzigGermany
  5. 5.Department of ControllingThe University Hospital of Cologne (AöR)CologneGermany

Personalised recommendations